| scholarly article | Q13442814 |
| P50 | author | Yoshihiro Kawaoka | Q2600945 |
| Makoto Ozawa | Q88586186 | ||
| P2093 | author name string | Yousuke Furuta | |
| Makoto Yamashita | |||
| Kei Takahashi | |||
| Maki Kiso | |||
| Kyoko Shinya | |||
| Hiroaki Katsura | |||
| Mai Thi Quynh Le | |||
| Masayuki Shimojima | |||
| Ryo Takano | |||
| Satoshi Kakugawa | |||
| P2860 | cites work | Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants | Q40308685 |
| A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza | Q43174483 | ||
| Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong | Q43174731 | ||
| Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. | Q43288467 | ||
| Resistant influenza A viruses in children treated with oseltamivir: descriptive study | Q45036693 | ||
| Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en | Q45384860 | ||
| Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. | Q45764995 | ||
| Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. | Q46620147 | ||
| Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro | Q21142648 | ||
| Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells | Q24559989 | ||
| CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity | Q24655526 | ||
| Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009 | Q28260987 | ||
| The potential impact of neuraminidase inhibitor resistant influenza | Q28299501 | ||
| Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants | Q28364114 | ||
| A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination | Q28471710 | ||
| Emergence of a novel swine-origin influenza A (H1N1) virus in humans | Q29616833 | ||
| Emergence and pandemic potential of swine-origin H1N1 influenza virus | Q29619003 | ||
| In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses | Q29619174 | ||
| Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice | Q29619193 | ||
| Influenza virus neuraminidase inhibitors | Q30305461 | ||
| Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. | Q30350180 | ||
| Avian flu: isolation of drug-resistant H5N1 virus. | Q30351638 | ||
| Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08 | Q30374740 | ||
| Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. | Q30378627 | ||
| Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection | Q30439560 | ||
| Position statement: global neuraminidase inhibitor susceptibility network | Q34294358 | ||
| Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors | Q34615286 | ||
| Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice | Q36949482 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pandemic | Q12184 |
| oseltamivir | Q211509 | ||
| P304 | page(s) | e1001079 | |
| P577 | publication date | 2010-08-26 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses | |
| Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses | |||
| P478 | volume | 6 |
| Q30390167 | A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro |
| Q30405350 | A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase |
| Q34036018 | A cutting-edge view on the current state of antiviral drug development |
| Q27024582 | Animal models for influenza virus pathogenesis, transmission, and immunology |
| Q30410899 | Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives |
| Q38633113 | Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies |
| Q34057596 | Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir |
| Q42280448 | Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009-2011. |
| Q37087113 | Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial |
| Q30364319 | Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice. |
| Q30419391 | Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation. |
| Q30425354 | Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses |
| Q34883401 | Considerations regarding appropriate sample size for conducting ferret transmission experiments |
| Q38161553 | Detection and management of antiviral resistance for influenza viruses |
| Q30405714 | Detection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand |
| Q35076785 | Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus |
| Q36785817 | Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice |
| Q30413246 | Efficient transmission of pandemic H1N1 influenza viruses with high-level oseltamivir resistance |
| Q28477046 | Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards |
| Q34339407 | Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses |
| Q28541953 | Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses |
| Q30414559 | Fitness of neuraminidase inhibitor-resistant influenza A viruses |
| Q37547236 | Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. |
| Q30352666 | Increased virulence of neuraminidase inhibitor-resistant pandemic H1N1 virus in mice: potential emergence of drug-resistant and virulent variants |
| Q39152320 | Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target. |
| Q37394266 | Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. |
| Q30360531 | Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea. |
| Q30378661 | Mapping influenza transmission in the ferret model to transmission in humans. |
| Q30400621 | Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. |
| Q30407925 | Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets |
| Q28477952 | Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic |
| Q59358022 | Neutralizing Anti-Hemagglutinin Monoclonal Antibodies Induced by Gene-Based Transfer Have Prophylactic and Therapeutic Effects on Influenza Virus Infection |
| Q48507448 | Neutralizing Antibodies Induced by Gene-Based Hydrodynamic Injection Have a Therapeutic Effect in Lethal Influenza Infection |
| Q30412407 | One-step detection of the 2009 pandemic influenza A(H1N1) virus by the RT-SmartAmp assay and its clinical validation |
| Q30409023 | Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience |
| Q30414483 | Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus in Northern Greece. |
| Q39092470 | Oseltamivir-resistant influenza A(H1N1)pdm09 virus in southern Brazil |
| Q30424185 | Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model |
| Q30397718 | Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness |
| Q92850538 | Polygalasaponin F treats mice with pneumonia induced by influenza virus |
| Q30367861 | Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. |
| Q30399480 | Proteotyping to establish gene origin within reassortant influenza viruses |
| Q26824804 | Quantification of viral infection dynamics in animal experiments |
| Q30392198 | Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice |
| Q28485404 | Reliability of a newly-developed immunochromatography diagnostic kit for pandemic influenza A/H1N1pdm virus: implications for drug administration |
| Q34576473 | Sample size considerations for one-to-one animal transmission studies of the influenza A viruses |
| Q30425350 | Surveillance for antiviral resistance |
| Q30423620 | Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening |
| Q38047645 | Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection |
| Q30410229 | The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses |
| Q30419738 | The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. |
| Q55155382 | The Marmoset as an Animal Model of Influenza: Infection With A(H1N1)pdm09 and Highly Pathogenic A(H5N1) Viruses via the Conventional or Tracheal Spray Route. |
| Q30406360 | The global spread of drug-resistant influenza |
| Q35761077 | Virological characterization of influenza H1N1pdm09 in Vietnam, 2010-2013. |
| Q30431823 | Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort |
Search more.